In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Israeli biotech Sol-Gel nets $80.2mm in Nasdaq IPO

Executive Summary

Five months after filing, dermatology-focused Israeli biotech Sol-Gel Technologies Ltd. (topical drug therapies) netted $80.2mm in a Nasdaq initial public offering of 7.2mm ordinary shares, including the overallotment, at $12. It had originally planned to offer 5mm shares at an $11-13 range.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Drug Delivery
      • Controlled Release
      • Topical Delivery
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies